Gladstone Institutional Advisory LLC Protagonist Therapeutics, Inc Transaction History

Gladstone Institutional Advisory LLC

  • $2 Billion
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022
SELL
$7.06 - $25.52 $67,987 - $245,757
-9,630 Closed
0 $0
Q1 2022

Jan 27, 2023
BUY
$23.34 - $36.08 $49,574 - $76,633
2,124 Added 28.3%
9,630 $228,000
Q1 2022

May 04, 2022
BUY
$23.34 - $36.08 $49,574 - $76,633
2,124 Added 28.3%
9,630 $228,000
Q4 2021

Jan 27, 2023
BUY
$17.63 - $37.1 $132,330 - $278,472
7,506 New
7,506 $257,000
Q4 2021

Feb 11, 2022
BUY
$17.63 - $37.1 $132,330 - $278,472
7,506 New
7,506 $257,000

Others Institutions Holding PTGX

# of Institutions
212
Shares Held
59.1M
Call Options Held
19K
Put Options Held
107K
View Full List

About Protagonist Therapeutics, Inc

PTGX Quotes by TradingView
  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $2.25B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Gladstone Institutional Advisory LLC Portfolio

Follow Gladstone Institutional Advisory LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gladstone Institutional Advisory LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gladstone Institutional Advisory LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email